Longevity Health Holdings, Inc. · OTC:XAGE
Longevity Health — Alpha Healthcare Acquisition Corp III — SPAC Merger (July 2023)
32 slides from Longevity Health's SPAC merger presentation, Jul 6, 2023
Slide 1: Carmell Therapeutics Merger With Alpha Healthcare Acquisition Corp III
Carmell Therapeutics Merger With Alpha Healthcare Acquisition Corp III (Nasdaq: ALPA) July 6, 2023
Slide 2: Presenters
PRESENTERS Rajiv Shukla Chairman & CEO, Alpha Healthcare Acquisition Corp. III Executive Chairman of “New Carmell” • 4-time public company CEO, since 2013 • Served as Director on the Boards of 14 companies • Raised $500+ million via IPO+PIPE as CEO since 2017 • Closed ~$65 billion in healthcare acqu
Slide 3: Background
BACKGROUND 1. Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) and Carmell Therapeutics announced the execution of a definitive Merger Agreement on January 4, 2023 2. Shareholder Vote to consider the Merger is scheduled for July 11, 2023 for shareholders as of Record Date of June 20, 2023 3. Re
Slide 4: Carmell Investment Highlights
CARMELL INVESTMENT HIGHLIGHTS 1. Platform product with multiple therapeutic applications 2. Clinical proof of concept from Phase II trial 3. Fast Track designation granted by the US FDA for Phase 2 candidate 4. 21 issued patents valid until 2031 5. Deeply experienced team with shared experience at J
Slide 5: Carmell Technology Platform: Allogeneic Pooled PRP
CARMELL TECHNOLOGY PLATFORM: Allogeneic Pooled PRP Carmell Allogeneic PRP Potential Benefits of Carmell PRP • Pooled plasma from healthy volunteers • Ready to use. Projected shelf life of 1-2 years potentially delivers better platelet counts vs • Bioactive for weeks at application site a patient’s o
Slide 6: Carmell Product Pipeline
CARMELL PRODUCT PIPELINE Development Applications Indication Comments Stage HEAL II (Healing Enhanced & Accelerated in Long-bone Tibia Fracture Healing fracture), FDA indicated study may proceed under existing Phase II (FDA Fast Track Granted) IND. CRO agreements signed and study preparation on-goin
Slide 7: Positioning Carmell for Success
POSITIONING CARMELL FOR SUCCESS Goal Strategy Rationale Build skin & hair • Aesthetics: Alopecia and skin rejuvenation • Fragmented markets with mix of mid-sized and rejuvenation—Develop innovative products inhouse, smaller companies (e.g., Merz, InMode, market leader starting with Alopecia Establis
Slide 8: Creating Shareholder Value: Acquisitions & Deal Making
CREATING SHAREHOLDER VALUE: ACQUISITIONS & DEAL MAKING Carmell THERAPEUTICS ALPA Nasdaq listed ALPA 100% Candy Merger Sub Carmell Therapeutics New Ticker: CTCX 100% Carmell Therapeutics CTCX 100% Carmell Therapeutics TargetCo 2 TargetCo 3 Target Evaluation Merger Announced in Jan 2023 Merger Closing
Slide 9: Non-Binding LOI to Acquire Commercial Stage Company
NON-BINDING LOI TO ACQUIRE COMMERCIAL STAGE COMPANY • Target manufactures and develops human allograft products for active soft tissue repair, aesthetics and orthopedic indications. • Target’s marketed products meet all criteria for regulation under section 361 of the PHS Act and 21 CFR part 1271 as
Slide 10: Soft Tissue Applications
SOFT TISSUE APPLICATIONS
Slide 11: US Aesthetics Market Is Growing Rapidly
US AESTHETICS MARKET IS GROWING RAPIDLY ~170 million Consumers aged 20-65 (men and women) ~80 million Addressable consumers with income>$50,000 ~15 million Have had an aesthetics procedure Consumer Spending, $ billions 40 ~1 million ~6 million 37 Had skin tightening procedure Had injectables procedu
Slide 12: Segmental Analysis of US Aesthetics Market
SEGMENTAL ANALYSIS OF US AESTHETICS MARKET SHOWS GROWTH IN SMALL TICKET CONSUMMABLES Carmell TM THERAPEUTICS Medical Aesthetics Manufacturer Revenue, $ billion $2 $1 $2 $1 2017 $4 $2 $3 $1 2022 $7 $3 $3 $1 2027 Injectables Skin Care Energy-based Devices Breast Implants CAGR 2022-27 11% 9% 6% 2% Sour
Slide 13: Hair Loss (Alopecia) Is a Large, Rapidly Growing Market
HAIR LOSS (ALOPECIA) IS A LARGE, RAPIDLY GROWING MARKET Carmell TM THERAPEUTICS Global Hair Transplant Market, $ billion1 28% CAGR $5.94 2018 $43.13 2026 35 million1 Men affected by alopecia in the US 250 million2 Men affected by alopecia in China Surgical Non-Surgical Procedure Types, 20181 Non-Sur
Slide 14: Alopecia Is One of the Top Unmet Needs in Aesthetics
ALOPECIA IS ONE OF THE TOP UNMET NEEDS IN AESTHETICS Carmell TM THERAPEUTICS APRIL 2022 DERMATOLOGY TIMES Linda Scotum, Associate Editor Patients with androgenetic alopecia (AGA) want better treatment options, according to survey results presented at both the 2022 Winter Clinical Dermatology Confere
Slide 15: What Is Androgenetic Alopecia (AGA)
WHAT IS ANDROGENETIC ALOPECIA (AGA) • Androgenetic alopecia (AGA), or hair loss mediated by the presence of the androgen dihydrotestosterone, is the most common form of alopecia in men and women1 • Almost all persons have some degree of AGA2. The hair loss usually begins between the ages of 12 and 4
Slide 16: Current AGA Treatments
CURRENT AGA TREATMENTS Carmell THERAPEUTICS Marketed AGA treatments : Prescription medications Over-the-counter medications Topical medications (prostaglandin analogs) Hair restoration surgery Low-Level Lasers Platelet-rich plasma Finasteride (Propecia®) Minoxidil (Rogaine®) Bimatoprost for eye lash
Slide 17: Minoxidil Is the Gold Standard for Treating AGA
MINOXIDIL IS THE GOLD STANDARD FOR TREATING AGA Minoxidil and its use in hair disorders: a review Drug Design, Development and Therapy 2019, Poonkiat Suchonwanit, Sasima Thammarucha, Kanchana Leerunyakul First introduced in the 1970’s as an oral medicine for severe hypertension Meta-analysis of mult
Slide 18: PRP Outperformed Minoxidil in Clinical Studies
PRP OUTPERFORMED MINOXIDIL IN CLINICAL STUDIES “PRP procedures had the largest share in aesthetic procedures for the last year and accounted for 58.1% of the total number of treatments. PRP has also shown promising results for hair rejuvenation and regrowth. It sends signals to the body which promot
Slide 19: Multiple Growth Factors Involved in Hair Growth
MULTIPLE GROWTH FACTORS INVOLVED IN HAIR GROWTH PRP Delivers These Growth Factors Stimulates dermal mesenchyme growth Induces & maintains anagen phase Promotes revascularization Improves hair growth & size Stimulates epithelial & fibroblast mitosis Improves anagen rate Slows apoptosis, stimulates fo
Slide 20: Hair Growth Observed in Clinical Trial With PRP (I)
HAIR GROWTH OBSERVED IN CLINICAL TRIAL WITH PRP (I) Carmell TM THERAPEUTICS The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized Placebo-Controlled Trial. Stem Cells Transl Med. 2015 Nov; 4(11): 1317–1323. Pietro Gentile 20 patients: 10 received placebo 10 received autologous PRP once a
Slide 21: Hair Growth Observed in Clinical Trial With PRP (II)
HAIR GROWTH OBSERVED IN CLINICAL TRIAL WITH PRP (II) Carmell TM THERAPEUTICS Evaluating the Efficacy of Different Platelet-Rich Plasma Regimens for Management of Androgenetic Alopecia: A Single-Center, Blinded, Randomized Clinical Trial, 2018, American Society for Dermatologic Surgery, Amelia K. Hau
Slide 22: Pooled PRP Outperformed Autologous PRP in Comparative Clinical Trial
POOLED PRP OUTPERFORMED AUTOLOGOUS PRP IN TREATING AGA IN COMPARATIVE CLINICAL TRIAL Carmell ™THERAPEUTICS Comparison of the Efficacy of Homologous and Autologous Platelet-Rich Plasma (PRP) for Treating Androgenic Alopecia Aesth Plast Surg. 2017, Bilsev Ince 60 patients assigned to treatment groups
Slide 23: Orthopedic Applications
orthopedic applications
Slide 24: Phase II Clinical Trial (HEAL I) Summary: Tibia Fractures
PHASE II CLINICAL TRIAL (HEAL I) SUMMARY: TIBIA FRACTURES Study Design Study Results • Double arm (20 treatment/10 control) Carmell: 14 Control: 7 • Prospective, randomized, multi-center Test Parameters patients patients Patient Population Mean # of cortices w/ • Open tibia fractures 2.64 1.33 >75%
Slide 25: Phase II Study (HEAL II)
PHASE II STUDY (HEAL II) Target Open Tibia Fractures with IM Rodding Study Rationale SOC + application of Bone Healing Accelerant vs. SOC alone Key Results and Primary endpoints: Same composite endpoint as HEAL I (180-day x-ray + clinical) Design Elements • One-year follow-up • Enrollment anticipate
Slide 26: Foot & Ankle Fusion Program
FOOT & ANKLE FUSION PROGRAM Clinical Need: Carmell ™THERAPEUTICS Deterioration of cartilage between the bones in the foot and ankle due to age, injury or disease Standard of Care: • Fusion surgery - remove the cartilage and fuse the two ends of the bone together utilizing hardware such as pins, scre
Slide 27: Phase II Clinical Trial Summary: Foot & Ankle Fusion
PHASE II CLINICAL TRIAL SUMMARY: FOOT & ANKLE FUSION Bone Healing Accelerant (BHA) versus Autologous Bone Grafting (ABG) for Hindfoot or Ankle Arthrodesis Proposed Study Design Study Design (FDA feedback on synopsis Nov 2022) • Full protocol under development To evaluate the preliminary safety and e
Slide 28: US/EU Regulatory Pathway
US/EU REGULATORY PATHWAY • Current Status: FDA clearance of HEAL II trial US (BLA/CBER) – • FDA has agreed to CMC plan Combination Product • Clinical protocol approved EU Class III • Current Status: Clinical Trial Applications underway Medical Device • MDR application for CE mark in development • IS
Slide 29: Transaction Overview
TRANSACTION OVERVIEW 28
Slide 30: Transaction Summary
TRANSACTION SUMMARY Transaction Structure Capitalization & Use of Proceeds Transaction Timeline Post-Closing Carmell pre-money valuation of $150M Sponsor and Carmell insiders locked up for 12 months from Closing irrespective of stock price ALPA founder will forfeit 50% of Class B Founder Shares if $
Slide 31: Transaction Terms
TRANSACTION TERMS Sources*, $M Carmell Equity Rollover $150 ALPA Trust $154 Total Sources $304 Uses*, $M Carmell Equity Rollover $150 Cash to Balance Sheet $148 Transaction Expenses $6 Total Sources $304 Enterprise Value* Shares, million 32.84 Share price $10.00 Equity Value, $M $328.4 Net Cash, $M
Slide 32: Disclaimer
DISCLAIMER This presentation (“Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between Alpha Healthcare Acquisition Corp. III (“ALPA”) and Carmell Therapeutics
Alpha Healthcare Acquisition Corp III — SPAC Merger (July 2023) on 6ix